<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03929367</url>
  </required_header>
  <id_info>
    <org_study_id>IRB00056413</org_study_id>
    <nct_id>NCT03929367</nct_id>
  </id_info>
  <brief_title>PK Sampling After IV Oxytocin and Effects on Sensory Function in Healthy Volunteers</brief_title>
  <official_title>Pharmacokinetics of Intravenous Oxytocin and Effects on Sensory Function in Healthy Volunteers</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Wake Forest University Health Sciences</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Wake Forest University Health Sciences</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>Yes</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      The primary goal of this protocol is to model change in oxytocin concentrations in plasma&#xD;
      after intravenous (IV) administration. Additional measurements will be performed on sensory&#xD;
      function that could be influenced by oxytocin during later time periods when blood samples&#xD;
      are widely separated by time. This protocol will describe the pharmacokinetics (PK) of&#xD;
      intravenous oxytocin in healthy adult men and adult,non-pregnant women. PK samples will be&#xD;
      obtained after an injection of intravenous oxytocin 10 IU over 60 seconds.&#xD;
&#xD;
      Blood will be drawn for the PK samples prior to the oxytocin administration and then 11 times&#xD;
      after administration.&#xD;
&#xD;
      There are two additional measures which will assess two different aspects of sensory&#xD;
      function.&#xD;
&#xD;
      MEASURE 1: Light Touch Frequency Threshold In order to determine the highest frequency that&#xD;
      specific nerve fibers can respond to, a simple device that produces an oscillatory /&#xD;
      vibratory stimulus will be used on the hand. The subject places fingertips, palm, and palm&#xD;
      side of the wrist sequentially and the device is set to slowly decrease the frequency of&#xD;
      vibration from 1 kHz until the subject first perceives this. This is repeated three times at&#xD;
      each site and takes less than 5 minutes in total. This will be performed before the oxytocin&#xD;
      administration and 6 times after the administration of IV Oxytocin.&#xD;
&#xD;
      MEASURE 2: Sustained Heat The surface of the skin of the forearm or leg is heated to 113°F&#xD;
      using a computer controlled thermode for a period of 5 minutes. This will be done before the&#xD;
      IV Oxytocin and 4 times after the administration. A set of random thermal temperatures&#xD;
      (98°F-122°F) will also be applied to the skin of the leg or forearm before the IV Oxytocin&#xD;
      administration and 4 times after administration of IV Oxytocin.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The primary goal of this protocol is to model change in oxytocin concentrations in plasma&#xD;
      after intravenous administration, (oxytocin (Pitocin®), 10 IU) the investigators will also&#xD;
      acquire tests of sensory function that could be modulated by oxytocin during later time&#xD;
      periods when blood samples are widely separated by time. There are two measures which will&#xD;
      assess two different aspects of sensory function.&#xD;
&#xD;
      MEASURE 1: Light Touch Frequency Threshold Light touch is subserved by a group of myelinated&#xD;
      peripheral nerves with fast conduction in the Aβ range and which are capable of following&#xD;
      high frequencies, being responsible for the sensation of vibration. This capability of&#xD;
      individual nerve fibers to respond with high frequency also underlies our ability to sense a&#xD;
      light touch moving across the body surface as in brushing.&#xD;
&#xD;
      In preclinical studies investigators have shown that, following injury, these light touch&#xD;
      fibers lose their ability to follow high frequencies and, in some cases, no longer respond to&#xD;
      mechanical stimulation at all. Oxytocin, when perfused around the neuronal cell bodies of&#xD;
      these Aβ nerve fibers, partially restores their function, including their response to high&#xD;
      frequency stimulation.&#xD;
&#xD;
      In order to determine the highest frequency that Aβ nerve fibers can respond to, the&#xD;
      investigators have created a simple device that produces an oscillatory / vibratory stimulus&#xD;
      which can be used on the hand. The subject places fingertips, palm, and volar aspect of the&#xD;
      wrist sequentially and the device is set to slowly decrease the frequency of vibration from 1&#xD;
      kilohertz (kHz) until the participant first perceives this. This is repeated three times at&#xD;
      each site and takes under 5 minutes in total.&#xD;
&#xD;
      The investigators anticipate that oxytocin will have no effect on normal Aβ fibers and that&#xD;
      this measure will not change after oxytocin administration. This will provide important data&#xD;
      to contrast with the expected efficacy of oxytocin in the setting of injury, to be studied in&#xD;
      subsequent protocols.&#xD;
&#xD;
      MEASURE 2: Sustained Heat As part of a protocol used by the investigators in several studies,&#xD;
      the surface of the skin of the forearm or leg is heated to 45°C using a computer-controlled&#xD;
      thermode for a period of 5 minutes. This typically results in a slowly increasing pain&#xD;
      experience, peaking at 5 minutes in the mild to low moderate range and has been tolerated by&#xD;
      more than 150 subjects in studies over the past 14 years.&#xD;
&#xD;
      In an interim analysis of an ongoing clinical study in volunteers, the investigators noted&#xD;
      that spinal injection of oxytocin, 15 μg (equivalent to 9 IU), that pain from this sustained&#xD;
      heat was dramatically reduced over the 5 minutes of stimulus presentation. In contrast,&#xD;
      spinal oxytocin had no effect on the stimulus-response relationship of pain to noxious heat&#xD;
      over a 42-50°C range when the stimuli were presented for only 5 seconds. These data suggest&#xD;
      that oxytocin reduces C-fiber mediated signaling of sustained heat pain, likely through a&#xD;
      spinal site of action.&#xD;
&#xD;
      Drugs administered spinally have a much higher concentration in cerebrospinal fluid than&#xD;
      plasma. Nonetheless, spinally administered drugs are typically absorbed to an extent and with&#xD;
      a time course similar to that after intramuscular injection, and it is conceivable that the&#xD;
      effect on sustained heat pain investigators are seeing in the spinal study reflect peripheral&#xD;
      effects via systemic absorption. Thus, if the investigators see a similar reduction in&#xD;
      response to sustained heat in this protocol of intravenous administration, the investigators&#xD;
      will conclude that oxytocin is more likely activating peripherally than spinally.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">May 10, 2019</start_date>
  <completion_date type="Actual">March 1, 2020</completion_date>
  <primary_completion_date type="Actual">March 1, 2020</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <intervention_model_description>Single intravenous administration of oxytocin (Pitocin®), 10 IU</intervention_model_description>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Oxytocin Concentration</measure>
    <time_frame>2 minutes</time_frame>
    <description>Plasma concentrations of oxytocin at defined times after intravenous infusion</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Oxytocin Concentration</measure>
    <time_frame>5 minutes</time_frame>
    <description>Plasma concentrations of oxytocin at defined times after intravenous infusion</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Oxytocin Concentration</measure>
    <time_frame>10 minutes</time_frame>
    <description>Plasma concentrations of oxytocin at defined times after intravenous infusion</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Oxytocin Concentration</measure>
    <time_frame>15 minutes</time_frame>
    <description>Plasma concentrations of oxytocin at defined times after intravenous infusion</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Oxytocin Concentration</measure>
    <time_frame>30 minutes</time_frame>
    <description>Plasma concentrations of oxytocin at defined times after intravenous infusion</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Oxytocin Concentration</measure>
    <time_frame>45 minutes</time_frame>
    <description>Plasma concentrations of oxytocin at defined times after intravenous infusion</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Oxytocin Concentration</measure>
    <time_frame>60 minutes</time_frame>
    <description>Plasma concentrations of oxytocin at defined times after intravenous infusion</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Oxytocin Concentration</measure>
    <time_frame>90 minutes</time_frame>
    <description>Plasma concentrations of oxytocin at defined times after intravenous infusion</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Oxytocin Concentration</measure>
    <time_frame>120 minutes</time_frame>
    <description>Plasma concentrations of oxytocin at defined times after intravenous infusion</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Oxytocin Concentration</measure>
    <time_frame>180 minutes</time_frame>
    <description>Plasma concentrations of oxytocin at defined times after intravenous infusion</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Oxytocin Concentration</measure>
    <time_frame>240 minutes</time_frame>
    <description>Plasma concentrations of oxytocin at defined times after intravenous infusion</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Light Touch Frequency Threshold</measure>
    <time_frame>5 minutes</time_frame>
    <description>The frequency at which the vibration is perceived after intravenous oxytocin administration</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Light Touch Frequency Threshold</measure>
    <time_frame>20 minutes</time_frame>
    <description>The frequency at which the vibration is perceived after intravenous oxytocin administration</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Light Touch Frequency Threshold</measure>
    <time_frame>45 minutes</time_frame>
    <description>The frequency at which the vibration is perceived after intravenous oxytocin administration</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Light Touch Frequency Threshold</measure>
    <time_frame>60 minutes</time_frame>
    <description>The frequency at which the vibration is perceived after intravenous oxytocin administration</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Light Touch Frequency Threshold</measure>
    <time_frame>120 minutes</time_frame>
    <description>The frequency at which the vibration is perceived after intravenous oxytocin administration</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Light Touch Frequency Threshold</measure>
    <time_frame>180 minutes</time_frame>
    <description>The frequency at which the vibration is perceived after intravenous oxytocin administration</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Sustained Heat</measure>
    <time_frame>31 minutes</time_frame>
    <description>0-10 verbal pain score to a 45 degree Celsius stimulus after intravenous oxytocin administration; higher score denotes worse outcome.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Sustained Heat</measure>
    <time_frame>32 minutes</time_frame>
    <description>0-10 verbal pain score to a 45 degree Celsius stimulus after intravenous oxytocin administration; higher score denotes worse outcome.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Sustained Heat</measure>
    <time_frame>33 minutes</time_frame>
    <description>0-10 verbal pain score to a 45 degree Celsius stimulus after intravenous oxytocin administration; higher score denotes worse outcome.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Sustained Heat</measure>
    <time_frame>34 minutes</time_frame>
    <description>0-10 verbal pain score to a 45 degree Celsius stimulus after intravenous oxytocin administration; higher score denotes worse outcome.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Sustained Heat</measure>
    <time_frame>35 minutes</time_frame>
    <description>0-10 verbal pain score to a 45 degree Celsius stimulus after intravenous oxytocin administration; higher score denotes worse outcome.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Sustained Heat</measure>
    <time_frame>61 minutes</time_frame>
    <description>0-10 verbal pain score to a 45 degree Celsius stimulus after intravenous oxytocin administration; higher score denotes worse outcome.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Sustained Heat</measure>
    <time_frame>62 minutes</time_frame>
    <description>0-10 verbal pain score to a 45 degree Celsius stimulus after intravenous oxytocin administration; higher score denotes worse outcome.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Sustained Heat</measure>
    <time_frame>63 minutes</time_frame>
    <description>0-10 verbal pain score to a 45 degree Celsius stimulus after intravenous oxytocin administration; higher score denotes worse outcome.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Sustained Heat</measure>
    <time_frame>64 minutes</time_frame>
    <description>0-10 verbal pain score to a 45 degree Celsius stimulus after intravenous oxytocin administration; higher score denotes worse outcome.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Sustained Heat</measure>
    <time_frame>65 minutes</time_frame>
    <description>0-10 verbal pain score to a 45 degree Celsius stimulus after intravenous oxytocin administration; higher score denotes worse outcome.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Sustained Heat</measure>
    <time_frame>121 minutes</time_frame>
    <description>0-10 verbal pain score to a 45 degree Celsius stimulus after intravenous oxytocin administration; higher score denotes worse outcome.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Sustained Heat</measure>
    <time_frame>122 minutes</time_frame>
    <description>0-10 verbal pain score to a 45 degree Celsius stimulus after intravenous oxytocin administration; higher score denotes worse outcome.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Sustained Heat</measure>
    <time_frame>123 minutes</time_frame>
    <description>0-10 verbal pain score to a 45 degree Celsius stimulus after intravenous oxytocin administration; higher score denotes worse outcome.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Sustained Heat</measure>
    <time_frame>124 minutes</time_frame>
    <description>0-10 verbal pain score to a 45 degree Celsius stimulus after intravenous oxytocin administration; higher score denotes worse outcome.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Sustained Heat</measure>
    <time_frame>125 minutes</time_frame>
    <description>0-10 verbal pain score to a 45 degree Celsius stimulus after intravenous oxytocin administration; higher score denotes worse outcome.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Sustained Heat</measure>
    <time_frame>181 minutes</time_frame>
    <description>0-10 verbal pain score to a 45 degree Celsius stimulus after intravenous oxytocin administration; higher score denotes worse outcome.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Sustained Heat</measure>
    <time_frame>182 minutes</time_frame>
    <description>0-10 verbal pain score to a 45 degree Celsius stimulus after intravenous oxytocin administration; higher score denotes worse outcome.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Sustained Heat</measure>
    <time_frame>183 minutes</time_frame>
    <description>0-10 verbal pain score to a 45 degree Celsius stimulus after intravenous oxytocin administration; higher score denotes worse outcome.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Sustained Heat</measure>
    <time_frame>184 minutes</time_frame>
    <description>0-10 verbal pain score to a 45 degree Celsius stimulus after intravenous oxytocin administration; higher score denotes worse outcome.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Sustained Heat</measure>
    <time_frame>185 minutes</time_frame>
    <description>0-10 verbal pain score to a 45 degree Celsius stimulus after intravenous oxytocin administration; higher score denotes worse outcome.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">11</enrollment>
  <condition>Chronic Pain</condition>
  <arm_group>
    <arm_group_label>Oxytocin (Pitocin®), 10 IU</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Oxytocin 10 IU administered once per intravenous injection</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Oxytocin</intervention_name>
    <description>Single IV administration of oxytocin</description>
    <arm_group_label>Oxytocin (Pitocin®), 10 IU</arm_group_label>
    <other_name>Pitocin</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Male or female &gt; 18 and &lt; 60 years of age, Body Mass Index (BMI) &lt;40.&#xD;
&#xD;
          -  Generally in good health as determined by the Principal Investigator based on prior&#xD;
             medical history, American Society of Anesthesiologists physical status I or II&#xD;
&#xD;
          -  Normal blood pressure (systolic 90-140 mmHg; diastolic 50-90 mmHg) resting heart rate&#xD;
             45-100 beats per minute) without medication&#xD;
&#xD;
          -  Female subjects of child-bearing potential and those &lt; 1 year post-menopausal, must be&#xD;
             practicing highly effective methods of birth control such as hormonal methods&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Hypersensitivity, allergy, or significant reaction to any ingredient of Pitocin®&#xD;
&#xD;
          -  Any disease, diagnosis, or condition (medical or surgical) that, in the opinion of the&#xD;
             Principal Investigator, would place the subject at increased risk (active gynecologic&#xD;
             disease in which increased tone would be detrimental e.g., uterine fibroids with&#xD;
             ongoing bleeding), compromise the subject's compliance with study procedures, or&#xD;
             compromise the quality of the data&#xD;
&#xD;
          -  Women who are pregnant (positive result for serum pregnancy test at screening visit),&#xD;
             women who are currently nursing or lactating, women that have been pregnant within 2&#xD;
             years&#xD;
&#xD;
          -  Subjects with neuropathy, chronic pain, diabetes mellitus, or taking benzodiazepines&#xD;
             or pain medications on a daily basis.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>60 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>James Eisenach, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Wake Forest University Health Sciences</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Wake Forest Baptist Medical Center</name>
      <address>
        <city>Winston-Salem</city>
        <state>North Carolina</state>
        <zip>27157</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>July 2020</verification_date>
  <study_first_submitted>April 24, 2019</study_first_submitted>
  <study_first_submitted_qc>April 24, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">April 26, 2019</study_first_posted>
  <results_first_submitted>March 18, 2021</results_first_submitted>
  <results_first_submitted_qc>March 18, 2021</results_first_submitted_qc>
  <results_first_posted type="Actual">April 19, 2021</results_first_posted>
  <last_update_submitted>April 16, 2021</last_update_submitted>
  <last_update_submitted_qc>April 16, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">May 13, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Chronic Pain</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Oxytocin</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol and Statistical Analysis Plan</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>June 11, 2019</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/67/NCT03929367/Prot_SAP_001.pdf</document_url>
    </provided_document>
    <provided_document>
      <document_type>Informed Consent Form</document_type>
      <document_has_protocol>No</document_has_protocol>
      <document_has_icf>Yes</document_has_icf>
      <document_has_sap>No</document_has_sap>
      <document_date>March 19, 2020</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/67/NCT03929367/ICF_000.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <pre_assignment_details>None. All enrolled subjects completed the study.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Oxytocin (Pitocin®), 10 IU</title>
          <description>Oxytocin 10 IU administered once per intravenous injection&#xD;
Oxytocin: Single IV administration of oxytocin</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="11"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="11"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Oxytocin (Pitocin®), 10 IU</title>
          <description>Oxytocin 10 IU administered once per intravenous injection&#xD;
Oxytocin: Single IV administration of oxytocin</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="11"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="11"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="38" spread="13"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="11"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="6"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Ethnicity (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="11"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Not Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="11"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="11"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="11"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="11"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>BMI</title>
          <description>Body Mass Index</description>
          <units>kg/m^2</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="11"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="29" spread="3.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Height</title>
          <units>cm</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="11"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="173" spread="6.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Weight</title>
          <units>kg</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="11"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="86" spread="11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Light Touch Frequency Threshold</title>
          <description>The frequency at which the vibration is perceived before intravenous oxytocin administration</description>
          <units>Hz</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="11"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="731" spread="155"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sustained heat</title>
          <description>0-10 verbal pain score to a 45 degree Celsius stimulus before intravenous oxytocin administration; higher score denotes worse outcome.</description>
          <population>Technical failure in one subject, leaving only 10 evaluable</population>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <title>One minute</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="10"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value=".36" spread=".21"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Two minutes</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="10"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value=".68" spread=".32"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Three minutes</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="10"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value=".64" spread=".29"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Four minutes</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="11"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value=".82" spread=".25"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Five minutes</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="10"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1.32" spread=".3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Oxytocin Concentration</title>
        <description>Plasma concentrations of oxytocin at defined times after intravenous infusion</description>
        <time_frame>2 minutes</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Oxytocin (Pitocin®), 10 IU</title>
            <description>Oxytocin 10 IU administered once per intravenous injection&#xD;
Oxytocin: Single IV administration of oxytocin</description>
          </group>
        </group_list>
        <measure>
          <title>Oxytocin Concentration</title>
          <description>Plasma concentrations of oxytocin at defined times after intravenous infusion</description>
          <units>pg/ml</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="11"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1047" spread="556"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <non_inferiority_type>Other</non_inferiority_type>
            <non_inferiority_desc>Modeling of change of plasma oxytocin concentration over time using nonlinear canonical compartment model.</non_inferiority_desc>
            <param_type>Bayesian information criterion</param_type>
            <param_value>2</param_value>
            <ci_n_sides>2-Sided</ci_n_sides>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Oxytocin Concentration</title>
        <description>Plasma concentrations of oxytocin at defined times after intravenous infusion</description>
        <time_frame>5 minutes</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Oxytocin (Pitocin®), 10 IU</title>
            <description>Oxytocin 10 IU administered once per intravenous injection&#xD;
Oxytocin: Single IV administration of oxytocin</description>
          </group>
        </group_list>
        <measure>
          <title>Oxytocin Concentration</title>
          <description>Plasma concentrations of oxytocin at defined times after intravenous infusion</description>
          <units>pg/ml</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="11"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="587" spread="257"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Oxytocin Concentration</title>
        <description>Plasma concentrations of oxytocin at defined times after intravenous infusion</description>
        <time_frame>10 minutes</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Oxytocin (Pitocin®), 10 IU</title>
            <description>Oxytocin 10 IU administered once per intravenous injection&#xD;
Oxytocin: Single IV administration of oxytocin</description>
          </group>
        </group_list>
        <measure>
          <title>Oxytocin Concentration</title>
          <description>Plasma concentrations of oxytocin at defined times after intravenous infusion</description>
          <units>pg/ml</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="11"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="322" spread="136"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Oxytocin Concentration</title>
        <description>Plasma concentrations of oxytocin at defined times after intravenous infusion</description>
        <time_frame>15 minutes</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Oxytocin (Pitocin®), 10 IU</title>
            <description>Oxytocin 10 IU administered once per intravenous injection&#xD;
Oxytocin: Single IV administration of oxytocin</description>
          </group>
        </group_list>
        <measure>
          <title>Oxytocin Concentration</title>
          <description>Plasma concentrations of oxytocin at defined times after intravenous infusion</description>
          <units>pg/ml</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="11"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="202" spread="91"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Oxytocin Concentration</title>
        <description>Plasma concentrations of oxytocin at defined times after intravenous infusion</description>
        <time_frame>30 minutes</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Oxytocin (Pitocin®), 10 IU</title>
            <description>Oxytocin 10 IU administered once per intravenous injection&#xD;
Oxytocin: Single IV administration of oxytocin</description>
          </group>
        </group_list>
        <measure>
          <title>Oxytocin Concentration</title>
          <description>Plasma concentrations of oxytocin at defined times after intravenous infusion</description>
          <units>pg/ml</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="11"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="82" spread="40"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Oxytocin Concentration</title>
        <description>Plasma concentrations of oxytocin at defined times after intravenous infusion</description>
        <time_frame>45 minutes</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Oxytocin (Pitocin®), 10 IU</title>
            <description>Oxytocin 10 IU administered once per intravenous injection&#xD;
Oxytocin: Single IV administration of oxytocin</description>
          </group>
        </group_list>
        <measure>
          <title>Oxytocin Concentration</title>
          <description>Plasma concentrations of oxytocin at defined times after intravenous infusion</description>
          <units>pg/ml</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="11"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="41" spread="20"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Oxytocin Concentration</title>
        <description>Plasma concentrations of oxytocin at defined times after intravenous infusion</description>
        <time_frame>60 minutes</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Oxytocin (Pitocin®), 10 IU</title>
            <description>Oxytocin 10 IU administered once per intravenous injection&#xD;
Oxytocin: Single IV administration of oxytocin</description>
          </group>
        </group_list>
        <measure>
          <title>Oxytocin Concentration</title>
          <description>Plasma concentrations of oxytocin at defined times after intravenous infusion</description>
          <units>pg/ml</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="11"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="25" spread="13"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Oxytocin Concentration</title>
        <description>Plasma concentrations of oxytocin at defined times after intravenous infusion</description>
        <time_frame>90 minutes</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Oxytocin (Pitocin®), 10 IU</title>
            <description>Oxytocin 10 IU administered once per intravenous injection&#xD;
Oxytocin: Single IV administration of oxytocin</description>
          </group>
        </group_list>
        <measure>
          <title>Oxytocin Concentration</title>
          <description>Plasma concentrations of oxytocin at defined times after intravenous infusion</description>
          <units>pg/ml</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="11"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10" spread="5.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Oxytocin Concentration</title>
        <description>Plasma concentrations of oxytocin at defined times after intravenous infusion</description>
        <time_frame>120 minutes</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Oxytocin (Pitocin®), 10 IU</title>
            <description>Oxytocin 10 IU administered once per intravenous injection&#xD;
Oxytocin: Single IV administration of oxytocin</description>
          </group>
        </group_list>
        <measure>
          <title>Oxytocin Concentration</title>
          <description>Plasma concentrations of oxytocin at defined times after intravenous infusion</description>
          <units>pg/ml</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="11"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.2" spread="3.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Oxytocin Concentration</title>
        <description>Plasma concentrations of oxytocin at defined times after intravenous infusion</description>
        <time_frame>180 minutes</time_frame>
        <population>In 7 subjects oxytocin concentration was below the limit of detection (1 pg/ml)</population>
        <group_list>
          <group group_id="O1">
            <title>Oxytocin (Pitocin®), 10 IU</title>
            <description>Oxytocin 10 IU administered once per intravenous injection&#xD;
Oxytocin: Single IV administration of oxytocin</description>
          </group>
        </group_list>
        <measure>
          <title>Oxytocin Concentration</title>
          <description>Plasma concentrations of oxytocin at defined times after intravenous infusion</description>
          <population>In 7 subjects oxytocin concentration was below the limit of detection (1 pg/ml)</population>
          <units>pg/ml</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="4"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.5" spread="1.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Oxytocin Concentration</title>
        <description>Plasma concentrations of oxytocin at defined times after intravenous infusion</description>
        <time_frame>240 minutes</time_frame>
        <population>In 9 subjects oxytocin concentration was below the limit of detection (1 pg/ml)</population>
        <group_list>
          <group group_id="O1">
            <title>Oxytocin (Pitocin®), 10 IU</title>
            <description>Oxytocin 10 IU administered once per intravenous injection&#xD;
Oxytocin: Single IV administration of oxytocin</description>
          </group>
        </group_list>
        <measure>
          <title>Oxytocin Concentration</title>
          <description>Plasma concentrations of oxytocin at defined times after intravenous infusion</description>
          <population>In 9 subjects oxytocin concentration was below the limit of detection (1 pg/ml)</population>
          <units>pg/ml</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="2"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.0" spread="1.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Light Touch Frequency Threshold</title>
        <description>The frequency at which the vibration is perceived after intravenous oxytocin administration</description>
        <time_frame>5 minutes</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Oxytocin (Pitocin®), 10 IU</title>
            <description>Oxytocin 10 IU administered once per intravenous injection&#xD;
Oxytocin: Single IV administration of oxytocin</description>
          </group>
        </group_list>
        <measure>
          <title>Light Touch Frequency Threshold</title>
          <description>The frequency at which the vibration is perceived after intravenous oxytocin administration</description>
          <units>Hz</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="11"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="722" spread="141"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <non_inferiority_desc>Light touch detection frequency was compared over time in comparison to baseline using a one way analysis of variance for repeated measures. A power analysis was not performed for this secondary outcome measure.</non_inferiority_desc>
            <p_value>.89</p_value>
            <p_value_desc>No effect</p_value_desc>
            <method>ANOVA</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Light Touch Frequency Threshold</title>
        <description>The frequency at which the vibration is perceived after intravenous oxytocin administration</description>
        <time_frame>20 minutes</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Oxytocin (Pitocin®), 10 IU</title>
            <description>Oxytocin 10 IU administered once per intravenous injection&#xD;
Oxytocin: Single IV administration of oxytocin</description>
          </group>
        </group_list>
        <measure>
          <title>Light Touch Frequency Threshold</title>
          <description>The frequency at which the vibration is perceived after intravenous oxytocin administration</description>
          <units>Hz</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="11"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="710" spread="130"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Light Touch Frequency Threshold</title>
        <description>The frequency at which the vibration is perceived after intravenous oxytocin administration</description>
        <time_frame>45 minutes</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Oxytocin (Pitocin®), 10 IU</title>
            <description>Oxytocin 10 IU administered once per intravenous injection&#xD;
Oxytocin: Single IV administration of oxytocin</description>
          </group>
        </group_list>
        <measure>
          <title>Light Touch Frequency Threshold</title>
          <description>The frequency at which the vibration is perceived after intravenous oxytocin administration</description>
          <units>Hz</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="11"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="732" spread="128"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Light Touch Frequency Threshold</title>
        <description>The frequency at which the vibration is perceived after intravenous oxytocin administration</description>
        <time_frame>60 minutes</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Oxytocin (Pitocin®), 10 IU</title>
            <description>Oxytocin 10 IU administered once per intravenous injection&#xD;
Oxytocin: Single IV administration of oxytocin</description>
          </group>
        </group_list>
        <measure>
          <title>Light Touch Frequency Threshold</title>
          <description>The frequency at which the vibration is perceived after intravenous oxytocin administration</description>
          <units>Hz</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="11"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="727" spread="127"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Light Touch Frequency Threshold</title>
        <description>The frequency at which the vibration is perceived after intravenous oxytocin administration</description>
        <time_frame>120 minutes</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Oxytocin (Pitocin®), 10 IU</title>
            <description>Oxytocin 10 IU administered once per intravenous injection&#xD;
Oxytocin: Single IV administration of oxytocin</description>
          </group>
        </group_list>
        <measure>
          <title>Light Touch Frequency Threshold</title>
          <description>The frequency at which the vibration is perceived after intravenous oxytocin administration</description>
          <units>Hz</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="11"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="693" spread="154"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Light Touch Frequency Threshold</title>
        <description>The frequency at which the vibration is perceived after intravenous oxytocin administration</description>
        <time_frame>180 minutes</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Oxytocin (Pitocin®), 10 IU</title>
            <description>Oxytocin 10 IU administered once per intravenous injection&#xD;
Oxytocin: Single IV administration of oxytocin</description>
          </group>
        </group_list>
        <measure>
          <title>Light Touch Frequency Threshold</title>
          <description>The frequency at which the vibration is perceived after intravenous oxytocin administration</description>
          <units>Hz</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="11"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="771" spread="99"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Sustained Heat</title>
        <description>0-10 verbal pain score to a 45 degree Celsius stimulus after intravenous oxytocin administration; higher score denotes worse outcome.</description>
        <time_frame>31 minutes</time_frame>
        <population>Technical failure in one subject, leaving 10 evaluable</population>
        <group_list>
          <group group_id="O1">
            <title>Oxytocin (Pitocin®), 10 IU</title>
            <description>Oxytocin 10 IU administered once per intravenous injection&#xD;
Oxytocin: Single IV administration of oxytocin</description>
          </group>
        </group_list>
        <measure>
          <title>Sustained Heat</title>
          <description>0-10 verbal pain score to a 45 degree Celsius stimulus after intravenous oxytocin administration; higher score denotes worse outcome.</description>
          <population>Technical failure in one subject, leaving 10 evaluable</population>
          <units>score on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="10"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.36" spread=".21"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Sustained Heat</title>
        <description>0-10 verbal pain score to a 45 degree Celsius stimulus after intravenous oxytocin administration; higher score denotes worse outcome.</description>
        <time_frame>32 minutes</time_frame>
        <population>Technical failure in one subject, leaving 10 evaluable</population>
        <group_list>
          <group group_id="O1">
            <title>Oxytocin (Pitocin®), 10 IU</title>
            <description>Oxytocin 10 IU administered once per intravenous injection&#xD;
Oxytocin: Single IV administration of oxytocin</description>
          </group>
        </group_list>
        <measure>
          <title>Sustained Heat</title>
          <description>0-10 verbal pain score to a 45 degree Celsius stimulus after intravenous oxytocin administration; higher score denotes worse outcome.</description>
          <population>Technical failure in one subject, leaving 10 evaluable</population>
          <units>score on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="10"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value=".14" spread=".14"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <non_inferiority_desc>Sustained heat score at the end of each 5 minute session was compared to baseline across time using a one-way analysis of variance for repeated measures. Power analysis was not performed for this secondary outcome measure.</non_inferiority_desc>
            <p_value>0.014</p_value>
            <method>ANOVA</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Sustained Heat</title>
        <description>0-10 verbal pain score to a 45 degree Celsius stimulus after intravenous oxytocin administration; higher score denotes worse outcome.</description>
        <time_frame>33 minutes</time_frame>
        <population>Technical failure in one subject, leaving 10 evaluable</population>
        <group_list>
          <group group_id="O1">
            <title>Oxytocin (Pitocin®), 10 IU</title>
            <description>Oxytocin 10 IU administered once per intravenous injection&#xD;
Oxytocin: Single IV administration of oxytocin</description>
          </group>
        </group_list>
        <measure>
          <title>Sustained Heat</title>
          <description>0-10 verbal pain score to a 45 degree Celsius stimulus after intravenous oxytocin administration; higher score denotes worse outcome.</description>
          <population>Technical failure in one subject, leaving 10 evaluable</population>
          <units>score on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="10"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value=".32" spread=".2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Sustained Heat</title>
        <description>0-10 verbal pain score to a 45 degree Celsius stimulus after intravenous oxytocin administration; higher score denotes worse outcome.</description>
        <time_frame>34 minutes</time_frame>
        <population>Technical failure in one subject, leaving 10 evaluable</population>
        <group_list>
          <group group_id="O1">
            <title>Oxytocin (Pitocin®), 10 IU</title>
            <description>Oxytocin 10 IU administered once per intravenous injection&#xD;
Oxytocin: Single IV administration of oxytocin</description>
          </group>
        </group_list>
        <measure>
          <title>Sustained Heat</title>
          <description>0-10 verbal pain score to a 45 degree Celsius stimulus after intravenous oxytocin administration; higher score denotes worse outcome.</description>
          <population>Technical failure in one subject, leaving 10 evaluable</population>
          <units>score on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="10"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value=".32" spread=".2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Sustained Heat</title>
        <description>0-10 verbal pain score to a 45 degree Celsius stimulus after intravenous oxytocin administration; higher score denotes worse outcome.</description>
        <time_frame>35 minutes</time_frame>
        <population>Technical failure in one subject, leaving 10 evaluable</population>
        <group_list>
          <group group_id="O1">
            <title>Oxytocin (Pitocin®), 10 IU</title>
            <description>Oxytocin 10 IU administered once per intravenous injection&#xD;
Oxytocin: Single IV administration of oxytocin</description>
          </group>
        </group_list>
        <measure>
          <title>Sustained Heat</title>
          <description>0-10 verbal pain score to a 45 degree Celsius stimulus after intravenous oxytocin administration; higher score denotes worse outcome.</description>
          <population>Technical failure in one subject, leaving 10 evaluable</population>
          <units>score on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="10"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value=".64" spread=".29"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Sustained Heat</title>
        <description>0-10 verbal pain score to a 45 degree Celsius stimulus after intravenous oxytocin administration; higher score denotes worse outcome.</description>
        <time_frame>61 minutes</time_frame>
        <population>Technical failure in one subject, leaving 10 evaluable</population>
        <group_list>
          <group group_id="O1">
            <title>Oxytocin (Pitocin®), 10 IU</title>
            <description>Oxytocin 10 IU administered once per intravenous injection&#xD;
Oxytocin: Single IV administration of oxytocin</description>
          </group>
        </group_list>
        <measure>
          <title>Sustained Heat</title>
          <description>0-10 verbal pain score to a 45 degree Celsius stimulus after intravenous oxytocin administration; higher score denotes worse outcome.</description>
          <population>Technical failure in one subject, leaving 10 evaluable</population>
          <units>score on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="10"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value=".45" spread=".33"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Sustained Heat</title>
        <description>0-10 verbal pain score to a 45 degree Celsius stimulus after intravenous oxytocin administration; higher score denotes worse outcome.</description>
        <time_frame>62 minutes</time_frame>
        <population>Technical failure in one subject, leaving 10 evaluable</population>
        <group_list>
          <group group_id="O1">
            <title>Oxytocin (Pitocin®), 10 IU</title>
            <description>Oxytocin 10 IU administered once per intravenous injection&#xD;
Oxytocin: Single IV administration of oxytocin</description>
          </group>
        </group_list>
        <measure>
          <title>Sustained Heat</title>
          <description>0-10 verbal pain score to a 45 degree Celsius stimulus after intravenous oxytocin administration; higher score denotes worse outcome.</description>
          <population>Technical failure in one subject, leaving 10 evaluable</population>
          <units>score on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="10"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value=".23" spread=".13"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Sustained Heat</title>
        <description>0-10 verbal pain score to a 45 degree Celsius stimulus after intravenous oxytocin administration; higher score denotes worse outcome.</description>
        <time_frame>63 minutes</time_frame>
        <population>Technical failure in one subject, leaving 10 evaluable</population>
        <group_list>
          <group group_id="O1">
            <title>Oxytocin (Pitocin®), 10 IU</title>
            <description>Oxytocin 10 IU administered once per intravenous injection&#xD;
Oxytocin: Single IV administration of oxytocin</description>
          </group>
        </group_list>
        <measure>
          <title>Sustained Heat</title>
          <description>0-10 verbal pain score to a 45 degree Celsius stimulus after intravenous oxytocin administration; higher score denotes worse outcome.</description>
          <population>Technical failure in one subject, leaving 10 evaluable</population>
          <units>score on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="10"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value=".27" spread=".15"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Sustained Heat</title>
        <description>0-10 verbal pain score to a 45 degree Celsius stimulus after intravenous oxytocin administration; higher score denotes worse outcome.</description>
        <time_frame>64 minutes</time_frame>
        <population>Technical failure in one subject, leaving 10 evaluable</population>
        <group_list>
          <group group_id="O1">
            <title>Oxytocin (Pitocin®), 10 IU</title>
            <description>Oxytocin 10 IU administered once per intravenous injection&#xD;
Oxytocin: Single IV administration of oxytocin</description>
          </group>
        </group_list>
        <measure>
          <title>Sustained Heat</title>
          <description>0-10 verbal pain score to a 45 degree Celsius stimulus after intravenous oxytocin administration; higher score denotes worse outcome.</description>
          <population>Technical failure in one subject, leaving 10 evaluable</population>
          <units>score on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="10"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value=".36" spread=".16"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Sustained Heat</title>
        <description>0-10 verbal pain score to a 45 degree Celsius stimulus after intravenous oxytocin administration; higher score denotes worse outcome.</description>
        <time_frame>65 minutes</time_frame>
        <population>Technical failure in one subject, leaving 10 evaluable</population>
        <group_list>
          <group group_id="O1">
            <title>Oxytocin (Pitocin®), 10 IU</title>
            <description>Oxytocin 10 IU administered once per intravenous injection&#xD;
Oxytocin: Single IV administration of oxytocin</description>
          </group>
        </group_list>
        <measure>
          <title>Sustained Heat</title>
          <description>0-10 verbal pain score to a 45 degree Celsius stimulus after intravenous oxytocin administration; higher score denotes worse outcome.</description>
          <population>Technical failure in one subject, leaving 10 evaluable</population>
          <units>score on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="10"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value=".73" spread=".25"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Sustained Heat</title>
        <description>0-10 verbal pain score to a 45 degree Celsius stimulus after intravenous oxytocin administration; higher score denotes worse outcome.</description>
        <time_frame>121 minutes</time_frame>
        <population>Technical failure in one subject, leaving 10 evaluable</population>
        <group_list>
          <group group_id="O1">
            <title>Oxytocin (Pitocin®), 10 IU</title>
            <description>Oxytocin 10 IU administered once per intravenous injection&#xD;
Oxytocin: Single IV administration of oxytocin</description>
          </group>
        </group_list>
        <measure>
          <title>Sustained Heat</title>
          <description>0-10 verbal pain score to a 45 degree Celsius stimulus after intravenous oxytocin administration; higher score denotes worse outcome.</description>
          <population>Technical failure in one subject, leaving 10 evaluable</population>
          <units>score on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="10"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value=".36" spread=".21"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Sustained Heat</title>
        <description>0-10 verbal pain score to a 45 degree Celsius stimulus after intravenous oxytocin administration; higher score denotes worse outcome.</description>
        <time_frame>122 minutes</time_frame>
        <population>Technical failure in one subject, leaving 10 evaluable</population>
        <group_list>
          <group group_id="O1">
            <title>Oxytocin (Pitocin®), 10 IU</title>
            <description>Oxytocin 10 IU administered once per intravenous injection&#xD;
Oxytocin: Single IV administration of oxytocin</description>
          </group>
        </group_list>
        <measure>
          <title>Sustained Heat</title>
          <description>0-10 verbal pain score to a 45 degree Celsius stimulus after intravenous oxytocin administration; higher score denotes worse outcome.</description>
          <population>Technical failure in one subject, leaving 10 evaluable</population>
          <units>score on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="10"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value=".23" spread=".13"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Sustained Heat</title>
        <description>0-10 verbal pain score to a 45 degree Celsius stimulus after intravenous oxytocin administration; higher score denotes worse outcome.</description>
        <time_frame>123 minutes</time_frame>
        <population>Technical failure in one subject, leaving 10 evaluable</population>
        <group_list>
          <group group_id="O1">
            <title>Oxytocin (Pitocin®), 10 IU</title>
            <description>Oxytocin 10 IU administered once per intravenous injection&#xD;
Oxytocin: Single IV administration of oxytocin</description>
          </group>
        </group_list>
        <measure>
          <title>Sustained Heat</title>
          <description>0-10 verbal pain score to a 45 degree Celsius stimulus after intravenous oxytocin administration; higher score denotes worse outcome.</description>
          <population>Technical failure in one subject, leaving 10 evaluable</population>
          <units>score on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="10"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value=".18" spread=".19"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Sustained Heat</title>
        <description>0-10 verbal pain score to a 45 degree Celsius stimulus after intravenous oxytocin administration; higher score denotes worse outcome.</description>
        <time_frame>124 minutes</time_frame>
        <population>Technical failure in one subject, leaving 10 evaluable</population>
        <group_list>
          <group group_id="O1">
            <title>Oxytocin (Pitocin®), 10 IU</title>
            <description>Oxytocin 10 IU administered once per intravenous injection&#xD;
Oxytocin: Single IV administration of oxytocin</description>
          </group>
        </group_list>
        <measure>
          <title>Sustained Heat</title>
          <description>0-10 verbal pain score to a 45 degree Celsius stimulus after intravenous oxytocin administration; higher score denotes worse outcome.</description>
          <population>Technical failure in one subject, leaving 10 evaluable</population>
          <units>score on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="10"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value=".27" spread=".2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Sustained Heat</title>
        <description>0-10 verbal pain score to a 45 degree Celsius stimulus after intravenous oxytocin administration; higher score denotes worse outcome.</description>
        <time_frame>125 minutes</time_frame>
        <population>Technical failure in one subject, leaving 10 evaluable</population>
        <group_list>
          <group group_id="O1">
            <title>Oxytocin (Pitocin®), 10 IU</title>
            <description>Oxytocin 10 IU administered once per intravenous injection&#xD;
Oxytocin: Single IV administration of oxytocin</description>
          </group>
        </group_list>
        <measure>
          <title>Sustained Heat</title>
          <description>0-10 verbal pain score to a 45 degree Celsius stimulus after intravenous oxytocin administration; higher score denotes worse outcome.</description>
          <population>Technical failure in one subject, leaving 10 evaluable</population>
          <units>score on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="10"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value=".77" spread=".37"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Sustained Heat</title>
        <description>0-10 verbal pain score to a 45 degree Celsius stimulus after intravenous oxytocin administration; higher score denotes worse outcome.</description>
        <time_frame>181 minutes</time_frame>
        <population>Technical failure in one subject, leaving 10 evaluable</population>
        <group_list>
          <group group_id="O1">
            <title>Oxytocin (Pitocin®), 10 IU</title>
            <description>Oxytocin 10 IU administered once per intravenous injection&#xD;
Oxytocin: Single IV administration of oxytocin</description>
          </group>
        </group_list>
        <measure>
          <title>Sustained Heat</title>
          <description>0-10 verbal pain score to a 45 degree Celsius stimulus after intravenous oxytocin administration; higher score denotes worse outcome.</description>
          <population>Technical failure in one subject, leaving 10 evaluable</population>
          <units>score on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="10"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value=".27" spread=".2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Sustained Heat</title>
        <description>0-10 verbal pain score to a 45 degree Celsius stimulus after intravenous oxytocin administration; higher score denotes worse outcome.</description>
        <time_frame>182 minutes</time_frame>
        <population>Technical failure in one subject, leaving 10 evaluable</population>
        <group_list>
          <group group_id="O1">
            <title>Oxytocin (Pitocin®), 10 IU</title>
            <description>Oxytocin 10 IU administered once per intravenous injection&#xD;
Oxytocin: Single IV administration of oxytocin</description>
          </group>
        </group_list>
        <measure>
          <title>Sustained Heat</title>
          <description>0-10 verbal pain score to a 45 degree Celsius stimulus after intravenous oxytocin administration; higher score denotes worse outcome.</description>
          <population>Technical failure in one subject, leaving 10 evaluable</population>
          <units>score on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="10"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value=".18" spread=".13"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Sustained Heat</title>
        <description>0-10 verbal pain score to a 45 degree Celsius stimulus after intravenous oxytocin administration; higher score denotes worse outcome.</description>
        <time_frame>183 minutes</time_frame>
        <population>Technical failure in one subject, leaving 10 evaluable</population>
        <group_list>
          <group group_id="O1">
            <title>Oxytocin (Pitocin®), 10 IU</title>
            <description>Oxytocin 10 IU administered once per intravenous injection&#xD;
Oxytocin: Single IV administration of oxytocin</description>
          </group>
        </group_list>
        <measure>
          <title>Sustained Heat</title>
          <description>0-10 verbal pain score to a 45 degree Celsius stimulus after intravenous oxytocin administration; higher score denotes worse outcome.</description>
          <population>Technical failure in one subject, leaving 10 evaluable</population>
          <units>score on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="10"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value=".32" spread=".15"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Sustained Heat</title>
        <description>0-10 verbal pain score to a 45 degree Celsius stimulus after intravenous oxytocin administration; higher score denotes worse outcome.</description>
        <time_frame>184 minutes</time_frame>
        <population>Technical failure in one subject, leaving 10 evaluable</population>
        <group_list>
          <group group_id="O1">
            <title>Oxytocin (Pitocin®), 10 IU</title>
            <description>Oxytocin 10 IU administered once per intravenous injection&#xD;
Oxytocin: Single IV administration of oxytocin</description>
          </group>
        </group_list>
        <measure>
          <title>Sustained Heat</title>
          <description>0-10 verbal pain score to a 45 degree Celsius stimulus after intravenous oxytocin administration; higher score denotes worse outcome.</description>
          <population>Technical failure in one subject, leaving 10 evaluable</population>
          <units>score on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="10"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value=".59" spread=".21"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Sustained Heat</title>
        <description>0-10 verbal pain score to a 45 degree Celsius stimulus after intravenous oxytocin administration; higher score denotes worse outcome.</description>
        <time_frame>185 minutes</time_frame>
        <population>Technical failure in one subject, leaving 10 evaluable</population>
        <group_list>
          <group group_id="O1">
            <title>Oxytocin (Pitocin®), 10 IU</title>
            <description>Oxytocin 10 IU administered once per intravenous injection&#xD;
Oxytocin: Single IV administration of oxytocin</description>
          </group>
        </group_list>
        <measure>
          <title>Sustained Heat</title>
          <description>0-10 verbal pain score to a 45 degree Celsius stimulus after intravenous oxytocin administration; higher score denotes worse outcome.</description>
          <population>Technical failure in one subject, leaving 10 evaluable</population>
          <units>score on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="10"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value=".86" spread=".22"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>1 day</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Oxytocin (Pitocin®), 10 IU</title>
          <description>This was a one day, open-label, single-dose study of intravenous oxytocin for the purpose of estimating plasma pharmacokinetic model parameters in adult men and women. Blood pressure, heart and respiratory rate, and oxyhemoglobin saturation were recorded prior to and at intervals following administration of oxytocin. In addition, subjects were informed to indicate if they had any subjective symptoms.</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="11"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="11"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>MedDRA (12.0)</default_vocab>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="11"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Facial flushing</sub_title>
                <description>Sensation of facial flushing lasting 2-12 minutes without visual appearance of flushing</description>
                <counts group_id="E1" events="7" subjects_affected="7" subjects_at_risk="11"/>
              </event>
              <event>
                <sub_title>Increased heart rate</sub_title>
                <description>Sensation of increased heart rate or heart pounding, but not accompanied by tachycardia or hypertension by direct measurement</description>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="11"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Headache</sub_title>
                <description>Mild headache lasting 2-12 min after oxytocin administration</description>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="11"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <limitations_and_caveats>Technical failure in one individual resulting in uninterpretable pain scores to sustained heat as a secondary outcome.</limitations_and_caveats>
    <point_of_contact>
      <name_or_title>Dr. James Eisenach</name_or_title>
      <organization>Wake Forest Health Sciences</organization>
      <phone>3367164182</phone>
      <email>eisenach@wakehealth.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

